Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Completed

Conditions studied: Neoplasms

In brief

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Key facts

Study ID

NCT00725387

Run by

Stanford University

People needed

214

Starts

2007-08-01

Expected to finish

2019-06-01

Last updated by the study team

2019-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients older than 18-year-old, diagnosed with cancer
• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

You may not qualify if…

• Patients who cannot complete a PET/CT scan
• Pregnant women
• Healthy volunteers
• Patients participating in other research studies
• The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States
• Aalborg Hospital — Aalborg, Denmark
• Apollo Hospital — Chennai, India
• Coimbra University Hospital — Coimbra, Portugal
• Pretoria Academic Hospital — Pretoria, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.